AbbVie's onabotulinumtoxinA moves toward approval for jawline contouring—a new indication that opens a fresh revenue stream.
The FDA has accepted a supplemental Biologics License Application for onabotulinumtoxinA to treat masseter muscle prominence, signaling movement toward a new cosmetic indication. This is distinct from the existing jaw-clenching (bruxism) approval and represents a direct play on the jawline-definition market that has grown alongside the GLP-1 boom.
Masseter reduction is already a high-margin procedure in practices using off-label toxin dosing. Formal indication status removes prescribing ambiguity and opens reimbursement pathways for patients seeking non-surgical jaw contouring. The sBLA pathway typically moves faster than a full BLA, meaning approval could arrive within months.
FDA acceptance of sBLA removes prescribing ambiguity and opens reimbursement pathways.
For practices, this matters because it legitimizes a procedure many are already performing, reduces liability exposure, and may unlock insurance coverage in select cases. It also signals AbbVie's willingness to expand Botox's cosmetic footprint beyond wrinkles—a defensive move against Revance's Daxxify and Evolus's Jeuveau in a crowded neuromodulator market.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
